Australia's Incannex Healthcare up on nod for clinical trial of sleep apnoea drug
06/07/2023 03:06
** Shares of Incannex Healthcare Ltd IHL.AX rise as much
as 9.5% to A$0.115, their highest level since June 16
** Clinical-stage pharmaceutical co receives approval from
Bellberry Human Research Ethics Committee
** Says approval to commence the
bioavailability/bioequivalence clinical trial of IHL-42X
** IHL-42X is a proprietary drug product for treatment of
obstructive sleep apnoea
** IHL down 40% YTD, as of last close
(Reporting by John Biju in Bengaluru)
((John.Biju@thomsonreuters.com;))
Recent news on Incannex Healthcare
See all newsBrief: Incannex Healthcare Says Computershare To Be Appointed As US Transfer Agent
Brief: Incannex Healthcare Says Federal Court Of Australia Approved Proposed Schemes Of Arrangement Between Incannex And Its Shareholders
Australia's Incannex up as shareholders in favour of US redomicile
Brief: Incannex Healthcare Will Prepare FDA Ind Application PSI-Gad
Brief: Review Of Ind Application For Ihl-42X By Us FDA Has Been Completed Clinical Trial For Patients With Obstructive Sleep Apnoea May Proceed